Multiple Myeloma | Specialty

Dr. Hari on Mitigating Selinexor-Related Toxicities in Multiple Myeloma

February 16th 2021

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Dr. Dhakal on Responses Achieved With Orva-Cel in Multiple Myeloma

February 16th 2021

Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.

Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma

February 12th 2021

Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.

Dr. D’Souza on the Utilization of Monoclonal Antibodies and Immunomodulating Agents in AL Amyloidosis

February 11th 2021

Anita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.

T-Cell Engagers and Combinations Push Myeloma Paradigm Forward

February 10th 2021

Sikander Ailawadhi, MD, discusses the future of relapsed/refractory multiple myeloma, the potential for retreatment with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and the promise of T-cell engagers in the field.

Future of MRD Assessment in NDMM

February 10th 2021

ASH Updates on Transplant in NDMM

February 10th 2021

Dr. D'Souza on Forming a Treatment Strategy for Relapsed AL Amyloidosis

February 10th 2021

Anita D’Souza, MD, discusses forming a treatment strategy for patients with relapsed light chain amyloidosis.

Novel Combinations Move Into the Spotlight in Early Relapsed Multiple Myeloma

February 9th 2021

Shaji K. Kumar, MD, discusses novel combinations that are being introduced to the relapsed/refractory setting in multiple myeloma, the value of minimal residual disease, and the importance of understanding potential toxicity when utilizing newer agents in the space.

Dr. Schmidt on the Clinical Implications of AMG 420 in Multiple Myeloma

February 8th 2021

Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.

Dr. Spencer on the Rationale to Evaluate Panobinostat in Multiple Myeloma

February 4th 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Dr. Dhakal on the Onset of CAR T-Cell Therapy–Induced CRS in Multiple Myeloma

February 3rd 2021

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

Individualized Induction Therapy for NDMM

February 3rd 2021

Approaching Early Treatment of High-Risk SMM

February 3rd 2021

MRD Could Prove to Be a Valuable Tool in Multiple Myeloma

February 1st 2021

Marc J. Braunstein, MD, PhD, discusses the current landscape of newly diagnosed multiple myeloma and the utility of minimal residual disease in the research sphere.

Influencing Factors to Initially Targeting BCMA in MM

February 1st 2021

Ongoing Approaches Toward Targeting BCMA

February 1st 2021

Next Steps for Use of Belantamab in Clinical Practice

February 1st 2021